Roche Holding AG / Disetronic Holding AG

Type 1 / Insulin-Dependent Diabetes Mellitus (Insulin Pump Therapy)

Disease Overview

Type 1 diabetes and insulin-dependent type 2 diabetes require continuous or multiple-daily insulin delivery. Insulin pumps deliver basal rates plus user-triggered bolus doses subcutaneously, improving glycemic control versus multiple daily injections. The pump market in 2003 was small but high-margin and growing alongside CGM adoption.

Competitive Landscape

In 2003 the global insulin pump market was effectively a duopoly: Medtronic MiniMed dominated the US (~75-80% share), and Disetronic was the clear #2 in the US and #1 in Europe with the H-Tron and D-Tron pumps. Smith's Medical's Deltec Cozmo and Animas (later acquired by J&J) were sub-scale challengers. Roche, already the global leader in blood glucose monitoring via its Accu-Chek franchise, paid SFr1.6B (~$1.18B) to combine pumps with meters and create an integrated diabetes management offering. The thesis was that closed-loop pump-plus-sensor systems would eventually win, and that owning both legs would lock in patient share. Execution disappointed: an FDA quality-system finding at the Swiss factory effectively kept Disetronic pumps out of the US market for ~2 years, and US pump share collapsed from ~20% in 2001 to under 4% by 2007. Roche relaunched the platform as Accu-Chek Spirit in 2006 but never recovered, eventually exiting US insulin pumps entirely in 2017. The deal is now widely cited as a cautionary tale of medtech integration risk.